Please find attached Outcome of Board Meeting.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Veerhealth Care's Board approved unaudited standalone financial results for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations more than doubled to ₹448.52 lakhs from ₹206.45 lakhs in Q1 FY25, a jump of about 117% year-on-year. Total revenue rose to ₹513.56 lakhs versus ₹242.26 lakhs. Net profit surged to ₹24.06 lakhs from ₹12.14 lakhs, nearly doubling, and EPS stood at ₹0.12 versus ₹0.06. The company also cleared the Director's Report for FY25 and fixed the 33rd AGM for September 30, 2025. The auditor (Jayesh R Shah & Co) issued an unqualified limited review report with no qualifications.
Strong top-line and bottom-line growth versus the year-ago quarter is a positive signal for shareholders, showing the healthcare pharma business scaling up after a small loss in Q4 FY25. Investors should watch whether this growth sustains in coming quarters and if margins hold, as expenses also grew sharply.